Malvern, PA — Progenra, Inc. a biotech company focused neurodegenerative drugs is pleased to announce the development of a new technology that will facilitate rapid discovery of drugs that work via Targeted Protein Degradation (TPD). A wave new drug candidate, called PROTACs or molecular glue drugs are emerging from pharmaceutical and biotech companies that work by degrading target proteins in human body. The paper highlights a key discovery in the application of Tandem Ubiquitin Binding Entities (TUBEs), a powerful technology developed by LifeSensors, Inc. The study, accepted for publication in Scientific Reports (Springer Nature), showcases a collaborative effort between Progenra and LifeSensors Inc. to rapidly discover TPD drugs by monitory ubiquitin chain linkages involved in cancer and inflammatory signaling, to uncover Molecular Glue and PROTAC-mediated protein degradation.
This technology represents a significant advance in rapid discovery of PROTACs and Molecular glue drugs which to date are discovered by traditional screening methods. Using chain-selective TUBE technology, the researchers were able to selectively capture and analyze specific ubiquitin linkages, providing new insights into the ubiquitination patterns that regulate both innate immune responses and targeted protein degradation by PROTACs. Progenra is employing this technology to develop molecular glue drug for Parkinson’s and Alzheimer’s disease.
Dr. Tauseef Butt, President and CEO of Progenra, commented, “We are excited to share this work, which demonstrates Progenra’s leading capabilities in decoding ubiquitination signatures critical to the function of PROTACs and molecular glues. A deep understanding of ubiquitin signaling is essential for the successful design of next-generation targeted protein degradation therapies.”
This publication underscores Progenra’s ongoing commitment to advancing the science of ubiquitin signaling and its therapeutic applications.
Progenra (www.progenra.com) is developing high value medicines exploiting protein regulatory pathways, molecular glues and PROTACs. Its product portfolio addresses unmet needs in neurodegeneration and cardiovascular diseases. Utilizing its UbiPro™ Drug Discovery Platform, Progenra identifies novel modulators of its protein regulatory targets for drug development; its discovery platform is complemented by internal target validation, cell proof of concept, and medicinal chemistry.